The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort

Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits

(2015) Norbert Schuff et al.   MOVEMENT DISORDERS

Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease

(2015) Daniel Weintraub et al.   MOVEMENT DISORDERS

PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer’s disease and Lewy body disorders

(2014) Andrew Siderowf et al.   BMC Neurology

Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123I-Ioflupane Injection (DaTscan) Imaging

(2014) J. P. Seibyl et al.   JOURNAL OF NUCLEAR MEDICINE

Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease

(2014) Daniela Berg et al.   MOVEMENT DISORDERS

The ongoing pursuit of neuroprotective therapies in Parkinson disease

(2014) Dilan Athauda et al.   Nature Reviews Neurology

Imaging prodromal Parkinson disease: The Parkinson Associated Risk Syndrome Study

(2014) D. Jennings et al.   NEUROLOGY

Longitudinal follow-up of SWEDD subjects in the PRECEPT Study

(2014) K. Marek et al.   NEUROLOGY

Parkinson Disease Subtypes

(2014) Mary Ann Thenganatt et al.   JAMA Neurology

Disease duration and the integrity of the nigrostriatal system in Parkinson’s disease

(2013) Jeffrey H. Kordower et al.   BRAIN

Recent developments in biomarkers in Parkinson disease

(2013) Anthony H.V. Schapira   CURRENT OPINION IN NEUROLOGY

Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial

(2013) Anthony HV Schapira et al.   LANCET NEUROLOGY

Genetic insights into common pathways and complex relationships among immune-mediated diseases

(2013) Miles Parkes et al.   NATURE REVIEWS GENETICS

Nonmotor and diagnostic findings in subjects with de novo Parkinson disease of the DeNoPa cohort

(2013) B. Mollenhauer et al.   NEUROLOGY

Characterizing mild cognitive impairment in incident Parkinson disease: The ICICLE-PD Study

(2013) A. J. Yarnall et al.   NEUROLOGY

European multicentre database of healthy controls for [123I]FP-CIT SPECT (ENC-DAT): age-related effects, gender differences and evaluation of different methods of analysis

(2012) Andrea Varrone et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Defining at-risk populations for Parkinson's disease: Lessons from ongoing studies

(2012) Daniela Berg et al.   MOVEMENT DISORDERS

Identifying prodromal Parkinson's disease: Pre-Motor disorders in Parkinson's disease

(2012) Ronald B. Postuma et al.   MOVEMENT DISORDERS

Total CSF α-synuclein is lower in de novo Parkinson patients than in healthy subjects

(2012) Brit Mollenhauer et al.   NEUROSCIENCE LETTERS

Neuropathology underlying clinical variability in patients with synucleinopathies

(2011) Glenda M. Halliday et al.   ACTA NEUROPATHOLOGICA

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI

(2011) Leslie M. Shaw et al.   ACTA NEUROPATHOLOGICA

α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study

(2011) Brit Mollenhauer et al.   LANCET NEUROLOGY

Cerebrospinal fluid amyloid   and tau in LRRK2 mutation carriers

(2011) J. O. Aasly et al.   NEUROLOGY

DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson’s disease

(2010) Zhen Hong et al.   BRAIN

CSF amyloid-  and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study

(2010) G. Alves et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cognitive-nigrostriatal relationships in de novo, drug-naïve Parkinson's disease patients: A [I-123]FP-CIT SPECT study

(2010) Flavio Nobili et al.   MOVEMENT DISORDERS

CSF Aβ42and tau in Parkinson's disease with cognitive impairment

(2010) Thomas J. Montine et al.   MOVEMENT DISORDERS

Teaching program for the movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale: (MDS-UPDRS)

(2010) Christopher G. Goetz et al.   MOVEMENT DISORDERS

The MoCA: Well-suited screen for cognitive impairment in Parkinson disease

(2010) J. C. Dalrymple-Alford et al.   NEUROLOGY

Safety of Lumbar Puncture Procedures in Patients with Alzheimers Disease

(2009) E. Peskind et al.   Current Alzheimer Research

The spectrum of neuropsychiatric symptoms in patients with early untreated Parkinson's disease

(2009) D Aarsland et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease

(2009) Daniel Weintraub et al.   MOVEMENT DISORDERS

Course in Parkinson disease subtypes: A 39-year clinicopathologic study

(2009) A. H. Rajput et al.   NEUROLOGY

An improved radiosynthesis of [18F]AV-133: a PET imaging agent for vesicular monoamine transporter 2

(2009) Lin Zhu et al.   NUCLEAR MEDICINE AND BIOLOGY

Cerebrospinal Fluid Biomarkers in Parkinson's Disease with Dementia and Dementia with Lewy Bodies

(2008) Lucilla Parnetti et al.   BIOLOGICAL PSYCHIATRY

Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results

(2008) Christopher G. Goetz et al.   MOVEMENT DISORDERS